5 Healthcare Stocks to Buy According to Billionaire DE Shaw

2. Moderna, Inc. (NASDAQ:MRNA)

D E Shaw Stake Value: $290,093,000
Percentage of D E Shaw’s 13F Portfolio: 0.26%
Number of Hedge Fund Holders: 49

Moderna, Inc. is a biotechnology business that develops messenger RNA-based medicines and vaccines for infectious illnesses, immuno-oncology, rare diseases, cardiovascular disorders, and auto-immune diseases. On December 6, Cowen analyst Tyler Van Buren initiated coverage of Moderna, Inc. (NASDAQ:MRNA), rating the stock as “Market Perform” and gave a price target of $250.

Out of the hedge funds being tracked by Insider Monkey, Coatue Management is a leading shareholder in Moderna, Inc. (NASDAQ:MRNA) with 6.05 million shares worth more than $2.33 billion. Even after selling 920,545 shares of Moderna, Inc. (NASDAQ:MRNA) in the third quarter, D E Shaw still holds 753,763 shares worth about $290.09 million.

Overall, hedge funds are loading up on Moderna, Inc. (NASDAQ:MRNA), as 49 out of the 867 funds tracked by Insider Monkey held stakes in the biotech company, compared to 37 funds a quarter earlier.

Carillon Tower Advisers, an investment management firm, in its third-quarter 2021 investor letter, mentioned Moderna, Inc. (NASDAQ:MRNA). Here is what the fund said:

“Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The stock proved to be an impressive contributor once again in the quarter, as investors continue to evaluate the potential for future growth driven primarily by the firm’s revolutionary COVID-19 vaccine. Strong global demand for the vaccine may persist for the foreseeable future in order to maintain immunity as well as provide protection against any additional future variants. The potential for the firm’s mRNA technology to be used in a number of other use cases, specifically influenza, could also provide an additional tailwind for future growth.”